9/23
08:00 am
actu
Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3ß Inhibitor
Medium
Report
Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3ß Inhibitor
9/16
08:00 am
actu
Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research
Medium
Report
Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research
9/11
08:00 am
actu
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
Low
Report
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
9/9
08:00 am
actu
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
Low
Report
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
9/5
09:10 am
actu
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Low
Report
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
8/20
09:00 am
actu
Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024
Medium
Report
Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024
8/14
04:05 pm
actu
Actuate Therapeutics Announces Closing of Initial Public Offering
Low
Report
Actuate Therapeutics Announces Closing of Initial Public Offering
8/12
08:27 pm
actu
Actuate Therapeutics Announces Pricing of Initial Public Offering
High
Report
Actuate Therapeutics Announces Pricing of Initial Public Offering